References

LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

10.1038/s41591-026-04262-4 · 2026 · External reference

Microglia- specific IL- 10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease

10.1126/scitranslmed.adm8563 · 2024 · External reference

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

2023 · External reference

Microglia and macrophages in brain homeostasis and disease

10.1038/nri.2017.125 · 2017 · External reference

Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes

10.1016/j.neuron.2024.06.029 · 2024 · External reference

Understanding the influence of TLR-mediated immune system on necroptosis-induced neurodegeneration in Parkinson’s disease

10.1016/j.arr.2025.102872 · 2025 · External reference

Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances

10.1038/s41392-025-02253-4 · 2025 · External reference

8-Oxoguanine causes neurodegeneration during MUTYH-mediated DNA base excision repair

10.1172/jci65053 · 2012 · External reference

Structure of a repair enzyme interrogating undamaged DNA elucidates recognition of damaged DNA

10.1038/nature03458 · 2005 · External reference

Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson’s disease and related neurodegenerative disorders

10.1007/s00401-004-0937-9 · 2004 · External reference

Structural mechanisms of NLRP3 inflammasome assembly and activation

10.1146/annurev-immunol-081022-021207 · 2023 · External reference

NLRP3 inflammasome in neuroinflammation and central nervous system diseases

10.1038/s41423-025-01275-w · 2025 · External reference

Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling

10.1016/j.immuni.2022.06.007 · 2022 · External reference

Identifying genetic targets in clinical subtypes of Parkinson’s disease for optimizing pharmacological treatment strategies

2024 · External reference

Baicalein (5,6,7-trihydroxyflavone) reduces oxidative stress-induced DNA damage by upregulating the DNA repair system

10.1007/s10565-012-9233-y · 2012 · External reference

A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein

2019 · External reference

Baicalein: multiple pharmacological activities, pharmacokinetics, and clinical trials

2024 · External reference

Procyanidins boost the neuroprotective effect of minocycline for intracerebral haemorrhage

10.1002/adfm.202303379 · 2023 · External reference

Pitavastatin-loaded procyanidins self-assembled nanoparticles alleviate advanced atherosclerosis via modulating macrophage efferocytosis and cholesterol efflux

10.1016/j.apsb.2024.08.006 · 2025 · External reference

Strategies for delivering therapeutics across the blood–brain barrier

10.1038/s41573-021-00139-y · 2021 · External reference

Acid-responsive dual-targeted nanoparticles encapsulated aspirin rescue the immune activation and phenotype in autism spectrum disorder

10.1002/advs.202104286 · 2022 · External reference

Artemisinin and Procyanidins loaded multifunctional nanocomplexes alleviate atherosclerosis via simultaneously modulating lipid influx and cholesterol efflux

10.1016/j.jconrel.2021.12.021 · 2022 · External reference

Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: insights and challenges

10.1016/j.jconrel.2023.06.023 · 2023 · External reference

Engineered nanoerythrocytes alleviate central nervous system inflammation by regulating the polarization of inflammatory microglia

10.1002/adma.202201322 · 2022 · External reference

Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles

10.1016/j.biomaterials.2009.02.051 · 2009 · External reference

Gene therapy for neuropathic pain through siRNA-IRF5 gene delivery with homing peptides to microglia

10.1016/j.omtn.2018.02.007 · 2018 · External reference

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

10.1186/s13059-014-0550-8 · 2014 · External reference

Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences

10.1093/bioinformatics/bty895 · 2019 · External reference

Controlling the false discovery rate: a practical and powerful approach to multiple testing

10.1111/j.2517-6161.1995.tb02031.x · 1995 · External reference

ClusterProfiler: an R package for comparing biological themes among gene clusters

10.1089/omi.2011.0118 · 2012 · External reference

The molecular signatures database (MSigDB) hallmark gene set collection

10.1016/j.cels.2015.12.004 · 2015 · External reference

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

10.1073/pnas.0506580102 · 2005 · External reference

Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release

2021 · External reference

MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration

10.1038/s41418-018-0124-5 · 2019 · External reference

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

10.1038/s41577-019-0165-0 · 2019 · External reference

Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation

10.1126/science.aar8048 · 2018 · External reference

Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function

10.1126/science.abf8980 · 2022 · External reference

OGG1 modulates the crosstalk of microglia and Müller cells in degenerative retinas via alleviating inflammatory response and oxidative stress

10.1016/j.exer.2025.110695 · 2026 · External reference

Enhanced mitochondrial DNA repair of the common disease-associated variant Ser326Cys of hOGG1 through small molecule intervention

10.1016/j.freeradbiomed.2018.05.094 · 2018 · External reference

Intracerebral fate of organic and inorganic nanoparticles is dependent on microglial extracellular vesicle function

10.1038/s41565-023-01551-8 · 2024 · External reference

Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy

10.1016/j.mtbio.2025.102343 · 2025 · External reference

Engineered extracellular vesicle-based nanoformulations that coordinate neuroinflammation and immune homeostasis, enhancing Parkinson’s disease therapy

10.1021/acsnano.4c04674 · 2024 · External reference

Corona composition can affect the mechanisms cells use to internalize nanoparticles

10.1021/acsnano.9b03824 · 2019 · External reference

The role and therapeutic potential of macropinocytosis in cancer

10.3389/fphar.2022.919819 · 2022 · External reference

Fructose-based single-chain polymer nanoparticles for GLUT1-mediated delivery: impact of polymer design on uptake and in vivo performance

10.1002/adhm.71345 · 2026 · External reference

Targeting the bile acid receptor TGR5 with Gentiopicroside to activate Nrf2 antioxidant signaling and mitigate Parkinson’s disease in an MPTP mouse model

10.1016/j.jare.2025.05.039 · 2026 · External reference

Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota

2021 · External reference

Structure of the human dopamine transporter in complex with cocaine

10.1038/s41586-024-07804-3 · 2024 · External reference

Involvement of neuroinflammation and oxidative stress in L-DOPA-induced dyskinesia in Parkinson’s disease: role of renin-angiotensin system and ROCK pathway

10.3390/antiox14101154 · 2025 · External reference

NIR-II imaging-guided photothermal activation of a TRPV4-targeted nanoplatform delivering cycloastragenol to promote microglia reprogramming and α-Synuclein clearance in Parkinson’s disease

10.1002/advs.202523380 · 2026 · External reference

Dual-pathway targeted therapy for Parkinson’s disease: biomimetic nanosomes inhibit ferroptosis and pyroptosis through NLRP3 inflammasome regulation

2025 · External reference

Gout while receiving levodopa for Parkinsonism

10.1001/jama.1972.03190270031008 · 1972 · External reference

The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson’s disease

10.1007/s10072-015-2471-z · 2016 · External reference

Recent advances in cell membrane-based biomimetic delivery systems for Parkinson’s disease: perspectives and challenges

2025 · External reference